Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo

by Franziska Briest, Eva J. Koziolek, Jakob Albrecht, Fränze Schmidt, Monique R. Bernsen, Joost Haeck, Anja A. Kühl, Dagmar Sedding, Teresa Hartung, Samantha Exner, Martina Welzel, Christian Fischer, Carsten Grötzinger, Winfried Brenner, Richard P. Baum, Patricia Grabowski
Published 2021-01-01